Dato-DXd NSQ NSCLC application withdrawn in EU
24 December 2024
Datopotamab deruxtecan application in the EU for patients with advanced
nonsquamous non-small cell lung cancer voluntarily withdrawn
AstraZeneca and Daiichi Sankyo…
94,671$
0,70%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
AZN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead the AstraZeneca Class Action Lawsuit
SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…
2 Excellent Dividend Stocks to Buy on the Dip
AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common. They are both leading drugmakers and have strong…
Astrazeneca: EU-Zulassung für Tagrisso gegen weitere Lungenkrebsform
AMSTERDAM/LONDON (dpa-AFX) - Der britische Pharmakonzern Astrazeneca darf sein Lungenkrebsmedikament Tagrisso in der EU in einer weiteren Indikation verkaufen.…
AZNs Tagrisso Gets Approval in the EU for Expanded Use in NSCLC
AstraZeneca wins approval in the EU for the label expansion of Tagrisso to treat adult patients with locally advanced, unresectable…